share_log

Goldman Sachs Initiates Coverage On Revance Therapeutics With Buy Rating, Announces Price Target of $33

Goldman Sachs Initiates Coverage On Revance Therapeutics With Buy Rating, Announces Price Target of $33

高盛以買入評級啓動對Revance Therapeutics的報道,宣佈目標股價爲33美元
Benzinga Real-time News ·  2022/09/22 06:21

Goldman Sachs analyst Chris Shibutani initiates coverage on Revance Therapeutics (NASDAQ:RVNC) with a Buy rating and announces Price Target of $33.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論